Level of Palliative Care Complexity in Advanced Cancer Patients: A Multinomial Logistic Analysis

Maria Isabel Carrasco-Zafra 1,2, Rafael Gómez-García 1,2, Ricardo Ocaña-Riola 3,4, Maria Luisa Martín-Rosell 1,2,5 and Encarnación Blanco-Reina 2,6,*

1 Fundación Cudeca, 29631 Málaga, Spain; maribelcarrasco@cudeca.org (M.I.C.-Z.); rafaelgomez@cudeca.org (R.G.-G.); marisamartin@cudeca.org (M.L.M.-R.)
2 Instituto de Investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain
3 Escuela Andaluza de Salud Pública, 18011 Granada, Spain; ricardo.ocana.easp@juntadeandalucia.es
4 Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
5 International Collaborative for Best Care for the Dying Person, Liverpool L3 9TA, UK
6 Pharmacology and Therapeutics Department, School of Medicine, University of Málaga, 29016 Málaga, Spain
* Correspondence: eblanco@uma.es; Tel.: +34-952-136-648; Fax: +34-952-131-568

Received: 17 May 2020; Accepted: 21 June 2020; Published: 23 June 2020

Abstract: The current treatment approach for patients in palliative care (PC) requires a health model based on shared and individualised care, according to the degree of complexity encountered. The aims of this study were to describe the levels of complexity that may be present, to determine their most prevalent elements and to identify factors that may be related to palliative complexity in advanced-stage cancer patients. An observational retrospective study was performed of patients attended to at the Cudeca Hospice. Socio-demographic and clinical data were compiled, together with information on the patients’ functional and performance status (according to the Palliative Performance Scale (PPS)). The level of complexity was determined by the Diagnostic Instrument of Complexity in Palliative Care (IDC-Pal©) and classified as highly complex, complex or non-complex. The impact of the independent variables on PC complexity was assessed by multinomial logistic regression analysis. Of the 501 patients studied, 44.8% presented a situation classed as highly complex and another 44% were considered complex. The highly complex items most frequently observed were the absence or insufficiency of family support and/or caregivers (24.3%) and the presence of difficult-to-control symptoms (17.3%). The complex item most frequently observed was an abrupt change in the level of functional autonomy (47.6%). The main factor related to the presence of high vs. non-complexity was that of performance status (odds ratio (OR) = 10.68, 95% confidence interval (CI) = 2.81–40.52, for PPS values < 40%). However, age was inversely related to high complexity. This study confirms the high level of complexity present in patients referred to a PC centre. Determining the factors related to this complexity could help physicians identify situations calling for timely referral for specialised PC, such as a low PPS score.

Keywords: palliative care; complexity; advanced cancer; health care systems

1. Introduction

The aim of palliative care (PC) is to improve the quality of life of patients and their families faced with advanced-stage life-threatening diseases [1]. Such interventions have proven effective in this regard [2,3] and, moreover, reduce the symptom burden [2,4]. PC is associated with improved care planning [2], greater patient and caregiver satisfaction with the care provided and lower levels of healthcare uptake [2,5,6].

The progressive aging of the population has increased the number of patients with chronic and advanced-stage diseases. In high-income countries, 69–82% of the population need PC before death,
J. Clin. Med. 2020, 9, 1960 2 of 12

with dementia and cancer accounting for most of the growth in this need [7,8]. However, current resources do not allow all patients with palliative needs to be adequately cared for by specialised PC teams, and in many cases healthcare providers are overwhelmed by the demand [8–10]. The inability to provide the end-of-life healthcare required is a major challenge to healthcare systems. Adding to the difficulty of the situation, complex clinical situations may arise during the course of the disease, requiring specialised resources. Early, accurate identification of such situations is essential [11–14]. In view of these considerations, it has been observed that the healthcare needs of patients and their families should be addressed by a model based on shared care. In other words, different levels and types of healthcare should be integrated and coordinated [11,12]. In such a system, initial PC would be provided by primary care services (family physician and home nursing) with basic palliative-medical qualifications, while more advanced needs would be met by PC specialists. However, in clinical practice, it is often difficult to identify patients who would profit from the provision of advanced resources, and the decision is often taken subjectively, according to the competence and beliefs of the medical professional attending the patient.

From an organisational standpoint, current trends in PC include the development of complementary models of attention based on levels of complexity. Although there is no standard definition of complexity, it seems clear that it is a multifactorial concept which not only encompasses patient-dependent elements, but is influenced by other aspects of the environment [14–16]. The Spanish National Health System has defined complexity as the set of factors presenting greater difficulty or intensity of needs, usually requiring the intervention of specialised PC services. It depends on the characteristics of the patient, on specific (sometimes difficult) problems, on the need for diagnostic or therapeutic action and on the family’s ability to adapt to the patient’s situation [17]. In order to provide appropriate individualised care and to coordinate the suitable health resources, it is essential to use standardised tools to establish the level of complexity presented [10,16,18].

In recent years, various studies have been undertaken to address the issue of complexity in PC. Some have taken a more theoretical approach, proposing models to clarify the issues involved [14–16,19], while others have proposed operative criteria for assessing complexity and the coordination of resources [20,21]. In this respect, and as part of the Andalusian Palliative Care Plan, the Diagnostic Instrument for Complexity in Palliative Care (IDC-Pal©) [22] has been developed and is in use in various healthcare environments [23–25]. This diagnostic tool evaluates a series of complexity elements, grouped into three dimensions (patient, family-social environment and healthcare organisation), on the basis of which the level of complexity is categorised as highly complex, complex or non-complex. This classification facilitates the decision-making task; for example, a highly complex situation would require the intervention of advanced or specific PC resources, while these would not be necessary in non-complex situations. Access to advanced resources should be based on the level of complexity, and appropriate assessment and referral protocols should be established. Knowing how to identify highly complex situations will allow for the early provision of those treatments and/or interventions by the interdisciplinary team that are more precise, in order to avoid unnecessary suffering for the patient and his/her family. The aim of this study is to describe the level of complexity presented by patients attended to at a PC centre, to determine which elements of complexity are most prevalent and to identify the factors that may be associated with PC complexity in advanced-stage cancer patients.

2. Patients and Methods

2.1. Study Design, Setting and Participants

This observational retrospective study was carried out at the Cudeca Hospice in Málaga (Spain), which is integrated into the public health system. On average, it provides PC to 1100 patients each year, via interdisciplinary teams composed of doctors, nurses, psychologists and social workers. The health resources at this hospice are an inpatient unit with nine rooms, six home PC teams and a day-care unit. The following inclusion criteria were applied: persons aged 18 years or older, with advanced-stage
cancer and who died between 1 August 2017 and 31 March 2018. All had been attended by the Cudeca Hospice, either at home or as inpatients.

2.2. Data Collection and Measures

The medical records of all the patients included in the study were reviewed, and the following data, obtained from the first clinical evaluation carried out by the PC team, were recorded for analysis: sociodemographic variables (age, sex and marital status); oncological variables (primary origin of the cancer, its extension and treatment received); functional status (according to the Barthel Index); performance status (according to the palliative performance scale (PPS)); and symptoms observed (pain, asthenia, anorexia, nausea-vomiting, constipation, dyspnoea, somnolence, insomnia, anxiety, depression). Information was also recorded on the service responsible for referring the patient to the PC programme, the characteristics of the main caregiver (sex, relationship) and the patient’s place of death.

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL), according to the degree of assistance required to perform ten actions related to mobility and self-care. On this scale, the higher the score, the greater the ability to function independently, as follows: total dependence (<20), highly dependent (20–39), partially dependent (40–59), minimally dependent (60–79) and independent (80–100) [26].

The PPS, a modification of the Karnofsky performance scale, is a useful tool for measuring the progressive physical decline of PC patients. It has five functional dimensions: ambulation, activity level and evidence of disease, self-care, oral intake and level of consciousness. The PPS has eleven levels, ranging from 100% (fully ambulatory and healthy) to 0% (death) in 10% steps. Each step represents a significant decrease in physical function [27].

The IDC-Pal© was used to measure the level of complexity presented, after the preliminary multidimensional assessment of the patient and his/her caregiver(s). The IDC-Pal© consists of 35 elements, 15 of which reflect a situation that is highly complex, while 20 represent one that is complex (Table S1). The instructions for the correct use of the instrument include a glossary to ensure that the elements identified accurately represent the contents referred to. When one or more high complexity items (HCIs) are observed, the PC situation is classed as highly complex; when there are no HCIs, but at least one complex item (CI), the situation is classed as complex; and when neither HCI nor CI are observed, the situation is classed as non-complex [22].

2.3. Statistical Analysis

A descriptive analysis was performed to establish the main sociodemographic and clinical characteristics presented by each patient. The baseline data are summarised by numerical data (mean, standard deviation and range) for the quantitative variables and by frequency tables for the qualitative variables.

A multinomial logistic regression model was used to study the relationship between the independent variables and the level of complexity established (i.e., situations classed as complex or highly complex, taking non-complexity as the reference standard) [28]. The independent variable PPS was classified by degree of functional deterioration, as follows: ≤40%, 50–60% and ≥70%. A 5% significance level was assumed to indicate statistical significance. Statistical data analysis was performed using SPSS version 23.0 (IBM SPSS Statistics, Armonk, NY, USA).

2.4. Ethical Considerations

The present study was approved by the Málaga Clinical Research Ethics Committee (project code EBR-SED-2017-1). The provisions of the Declaration of Helsinki, revised in 2013, regarding ethical principles for research on human beings, were fully complied with throughout this study.
3. Results

3.1. Characteristics of the Study Population

The study population was composed of 501 patients, with a mean age of 71 years (standard deviation 12.3, range 33–97), of whom 60.5% were male. Most were married or had a partner (61%). Of the main caregivers, 72% were women, although 6.1% of patients had no caregiver. The most frequent patient-caregiver relationship was that of a couple (37.2%) or parent-son/daughter (34.3%). Most of the patients had been referred for PC by the oncology service (66.5%), followed by other medical specialities (such as internal and digestive medicine) (18.9%) and primary care centres (14.6%). The main characteristics of the study population are detailed in Table 1.

Table 1. Characteristics of the study population (N = 501).

| Variables                        | Value          |
|----------------------------------|----------------|
| Age, mean (standard deviation)   | 71.5 (±12.3)   |
| Sex, n (%)                       |                |
| Male                             | 303 (60.5)     |
| Female                           | 198 (39.5)     |
| Marital status, n (%)            |                |
| Married or with partner          | 292 (61.0)     |
| Widowed                          | 99 (20.7)      |
| Divorced/separated               | 49 (10.2)      |
| Single                           | 39 (8.1)       |
| Main carer, n (%)                |                |
| Female                           | 323 (72.9)     |
| Male                             | 93 (21.0)      |
| No carer                         | 27 (6.1)       |
| Relationship with carer, n (%)   |                |
| Partner                          | 167 (37.2)     |
| Child (son/daughter)             | 154 (34.3)     |
| Agency referring for PC, n (%)   |                |
| Oncology service                 | 274 (66.5)     |
| Other specialities               | 78 (18.9)      |
| Primary care                     | 60 (14.6)      |
| Primary cancer, n (%)            |                |
| Gastrointestinal                 | 153 (33.8)     |
| Lung                             | 108 (23.8)     |
| Breast-Gynaecological            | 59 (13.0)      |
| Genito-Urinary                   | 51 (11.3)      |
| Head and neck                    | 24 (5.3)       |
| Haematological                   | 21 (4.6)       |
| Other                            | 37 (8.2)       |
| Cancer dissemination, n (%)      |                |
| Metastasis                       | 365 (73.8)     |
| Local                            | 110 (23.2)     |
| Cancer treatment, n (%)          |                |
| Yes                              | 322 (64.4)     |
| No                               | 163 (33.6)     |
| Barthel Index, n (%)             |                |
| 100                              | 62 (13.3)      |
| 80                               | 188 (40.4)     |
| 40–55                            | 115 (24.7)     |
| 20–35                            | 55 (11.8)      |
| 20                               | 45 (9.7)       |
| PPS, n (%)                       |                |
| ≥70%                             | 125 (26.0)     |
| 50–60%                           | 227 (47.2)     |
| ≤40%                             | 129 (26.8)     |
| Most frequent symptoms, n (%)    |                |
| Pain                             | 259 (52.6)     |
| Asthenia                         | 175 (35.6)     |
| Constipation                     | 139 (28.3)     |
| Dysphagia                        | 99 (20.3)      |
| Insomnia                         | 92 (18.7)      |
| Anorexia                         | 69 (14.0)      |
| Nausea/Vomiting                  | 66 (13.4)      |
| Somnolence                       | 40 (8.1)       |
| Depression                       | 36 (7.3)       |
| Anxiety                          | 35 (7.1)       |
| Place of death, n (%)            |                |
| Home                             | 234 (46.7)     |
| Public hospital                  | 148 (29.6)     |
| Inpatient Unit at Cudeca         | 119 (23.7)     |

PPS: Palliative Performance Scale.
The most prevalent primary tumours were gastrointestinal (33.8%) and pulmonary (23.8%). Metastatic dissemination was present in 76.8% of the patients. One third had not received any specific treatment for their cancer.

The Barthel Index score presented by 53.7% of the patients indicated minimal or no dependence for ADL, but 20%, at the first assessment, were found to be totally dependent. According to the PPS, almost half of the patients presented intermediate scores, while 26.8% obtained scores <40%. The most prevalent symptoms were pain (52.6%), asthenia (35.6%) and constipation (28.3%). Over half of the patients died during hospitalisation, either in a public hospital (29.6%) or in the admission unit at the Cudeca Hospice (23.7%) (Table 1).

3.2. Assessment of Complexity Level in Palliative Care

According to the IDC-Pal©, the situation of most of the patients considered was classed as complex or highly complex (44.0% and 44.8%, respectively). Only 11.2% presented none of the criteria for complexity. Each patient presented 0–8 CIs or HCIs, with an average of 1.8 (SD 1.3) and a median value of 2. Five or more elements of complexity or high complexity were observed in 22 patients.

The HCIs most frequently recorded were the lack or insufficiency of family support and/or caregivers (24.3%), the presence of difficult-to-control symptoms (17.3%) and the appearance of problematic clinical situations due to cancer progression (11.2%) (Table 2). The most prevalent CI was an abrupt change in the level of functional autonomy (47.6%), followed by social-family roles being performed by the patient (15.6%), severe constitutional syndrome (13.1%) and patient-family communication conflicts (11.8%) (Table 3). Some potential CIs did not affect the patients included in the present study, such as the application of difficult-to-manage palliative sedation or the existence of limited professional competence to address problematic situations.

| Items of High Complexity                                      | N (%) |
|--------------------------------------------------------------|-------|
| The patient is a child or adolescent                         | 0 (0.0) |
| Symptoms difficult to control                                | 82 (17.3) |
| Refractory symptoms                                          | 8 (1.7) |
| Urgent situation in the terminal cancer patient              | 14 (3.0) |
| Last hours/days of life difficult to control                 | 7 (1.5) |
| Clinical situation due to difficult-to-control cancer progression | 53 (11.2) |
| Risk of patient committing suicide                           | 4 (0.8) |
| Patient requests the process of death to be hastened         | 2 (0.4) |
| Patient presents existential distress and/or spiritual suffering | 7 (1.5) |
| Absence or insufficiency of family support and/or caregivers  | 115 (24.3) |
| Family members and/or caregivers not competent to give care  | 12 (2.5) |
| Dysfunctional family                                         | 6 (1.3) |
| Family and/or caregiver burden                                | 6 (1.3) |
| Structural limitations of environment for the patient         | 8 (1.7) |
| Application of palliative sedation difficult to manage        | 0 (0.0) |
| Total of patients with at least one item of high complexity   | 216 (44.8) |

Among the study population, the patients in situations of high complexity, according to IDC-Pal©, were more likely to die in hospital than those in non-complex situations (64.3% vs. 51.9%, respectively).
Table 3. Number of patients with a complex situation, according to IDC-Pal©.

| Items of Complexity                                                                  | N (%) |
|---------------------------------------------------------------------------------------|-------|
| The patient is a healthcare professional                                                 | 3 (0.6) |
| Social-family role performed by the patient                                              | 74 (15.6) |
| Previous physical, psychological or sensorial disability                                | 23 (4.9) |
| Recent and/or active addiction problems                                                 | 7 (1.5) |
| Previous mental illness                                                                  | 12 (2.5) |
| Acute decompensated organ insufficiency in non-oncological terminal patient              | 0 (0.0) |
| Severe cognitive failure                                                                 | 23 (4.9) |
| Abrupt change in level of functional autonomy                                            | 225 (47.6) |
| Presence of difficult-to-control comorbidity                                             | 19 (4.0) |
| Severe constitutional syndrome                                                          | 62 (13.1) |
| Clinical management difficult due to repeated non-compliance with therapy                 | 15 (3.2) |
| Communication conflicts between patient and family                                       | 56 (11.8) |
| Communication conflicts between patient and healthcare team                              | 17 (3.6) |
| Inadequate emotional coping by patient                                                   | 3 (0.6) |
| Complex bereavement                                                                     | 5 (1.1) |
| Difficulty in the indication and/or management of medication                            | 2 (0.4) |
| Difficulty in the indication and/or management of interventions                         | 1 (0.2) |
| Limitations of professional competence to address situations                            | 0 (0.0) |
| Difficulty in managing or acquiring instrumental techniques and/or specific material at home | 3 (0.6) |
| Difficulty in managing coordination and logistic needs                                   | 2 (0.4) |
| Total of patients with at least one item of complexity                                  | 212 (44.0) |

3.3. Factors Related to Complexity Level

To further examine the impact of the independent variables on the PC complexity categories, a multinomial logistic regression analysis was performed. This analysis showed that the main factor related to high vs. non-complexity is the performance status. Thus, a patient whose PPS is <40% is ten times more likely to present a situation of high complexity (odds ratio (OR) = 10.68, 95% confidence interval (CI) = 2.81–40.52), while a PPS of 50–60% triples this risk (OR = 3.27, 95% CI = 1.45–7.35) (reference level: PPS >70%). However, age is inversely related to high complexity. All other variables being equal, for each additional year of life, the odds of the patient having a highly complex palliative situation decrease by 4% (Table 4).

The presence of complexity with respect to non-complexity is also related to the PPS; patients who start PC with PPS <40% are eight times more likely to have a complex situation (OR = 7.98, 95% CI = 2.11–30.22). In addition, the presence of dyspnoea in the initial PC assessment triples the odds of complexity (OR = 3.24, 95% CI = 1.06–9.91). A similar pattern for the age effect was observed, but in this case the difference was not statistically significant (Table 4). Neither the patient’s sex, nor the presence of metastases, that of other frequent symptoms (pain and asthenia), the level of health care provided or the type of medical service referring the patient to the PC centre were predictors of complexity.
Table 4. Factors related to level of palliative complexity. Multinomial logistic regression for high complexity and complexity (with respect to non-complexity).

| Independent Variable          | OR (95% CI) High Complexity | OR (95% CI) Complexity |
|------------------------------|-----------------------------|------------------------|
| Age                          | 0.96 (0.93–0.99) *          | 0.98 (0.95–1.01)       |
| Sex                          |                             |                        |
| Female                       | 1.12 (0.55–2.50)            | 1.23 (0.56–2.70)       |
| Male                         | 1                           | 1                      |
| Agency referring for PC      |                             |                        |
| Primary care                 | 2.17 (0.48–9.87)            | 1.11 (0.24–5.10)       |
| Oncology                     | 1.35 (0.51–3.57)            | 1.26 (0.49–3.22)       |
| Other hospital service       | 1                           | 1                      |
| Metastasis                   |                             |                        |
| Yes                          | 1.01 (0.44–2.71)            | 1.27 (0.52–3.12)       |
| No                           | 1                           | 1                      |
| PPS                          |                             |                        |
| PPS < 40%                    | 10.68 (2.81–40.52) ***      | 7.98 (2.11–30.22) **   |
| PPS 50–60%                   | 3.27 (1.45–7.35) **         | 3.58 (1.26–7.90) **    |
| PPS > 70%                    | 1                           | 1                      |
| Pain                         |                             |                        |
| Yes                          | 1.26 (0.59–2.71)            | 0.93 (0.44–1.97)       |
| No                           | 1                           | 1                      |
| Dyspnoea                     |                             |                        |
| Yes                          | 2.55 (0.82–7.97)            | 3.24 (1.06–9.91) *     |
| No                           | 1                           | 1                      |
| Asthenia                     |                             |                        |
| Yes                          | 1.14 (0.51–2.53)            | 1.18 (0.54–2.61)       |
| No                           | 1                           | 1                      |

*p < 0.05; ** p < 0.01; *** p < 0.001. OR, Odds Ratio; 95% CI, 95% Confidence Interval; PPS, Palliative Performance Scale.

4. Discussion

The main aim of this study is to determine the levels of complexity presented by advanced-stage cancer patients attended to at a PC centre and to identify factors that may be associated with this complexity. According to the IDC-Pal© results obtained, 88.8% of the study population presented at least one CI or HCI. Among the complexity criteria most frequently observed were those corresponding to the clinical dimension; many patients underwent an abrupt decrease in their level of functional autonomy (CI) and presented difficult-to-control symptoms (HCI). These results are consistent with those of previous research, in which the presence of physical symptoms is the most frequently-cited criterion for the use of specific PC resources [21,24,29]. However, it is interesting to note that up to a third of the patients in our study population presented one or more elements of complexity related to the family and to the patient’s environment; in this respect, the absence or insufficiency of family support and/or caregivers was most commonly observed.

To date, very few studies have been undertaken to assess the level of complexity in PC. However, within this limited research, two teams of researchers, also using IDC-Pal©, have detected high complexity in around 65% of the patients considered. In both cases, the items most frequently identified coincide with those obtained in the present study (i.e., an abrupt fall in the level of functional autonomy, the appearance of difficult-to-control symptoms and the social-family role performed by the patient) [23,24]. Another study proposed a predictive model of complexity in PC (PALCOM) to identify multidimensional variables that influence the level of complexity in patients with advanced-stage cancer. According to these authors, 41% of their patients presented high levels of PC complexity and in another 42.9% the complexity was classed as “medium” [21]. In view of these findings, and our own study results, we conclude that there is a significant prevalence of moderate and high levels of complexity among these types of patients, and that in most cases their referral to the PC centre is appropriate and timely.
The factors most strongly related to the level of complexity are performance status, age and the presence of dyspnoea. According to our multinomial logistic regression model, the most consistent predictor of complex and highly complex situations is the performance status; thus, PPS values <40% increase the likelihood of moderate or high levels of complexity by 8 and 10 times, respectively. This association is a novel finding; to our knowledge, the previous use of PPS has mainly been limited to the initial assessment for an end-of-life prognosis and for the prediction of survival [30,31]. However, we believe this finding is logical and consistent with the fact that the sudden appearance of disabling functional impairment is the most frequent element of complexity among the patients studied. Regular, systematic assessment by the PPS could facilitate the prompt identification of any decline in performance status and enable timely referral for supportive and PC services [32], thus enhancing patients’ quality of life [2,3,33]. In practical terms, as soon as a patient’s PPS score falls below about 40–50%, this would suggest the time is appropriate to review options for end-of-life care to be provided by specialised PC teams.

Among the physical symptoms most frequently observed at the initial assessment of the patients in our study (pain, dyspnoea and asthenia), the most significant is dyspnoea, the presence of which triples the likelihood of complexity. The complex biopsychosocial aetiology of this symptom and its manifestations make it particularly challenging to control [34]. Dyspnoea is very distressing for patients and their families, and in itself may have a secondary impact on functional status.

Our investigation revealed an inverse relationship between advanced age and the likelihood of high complexity. This finding corroborates the previous work of Hodiamont, who reported that the patient’s age is a factor that may influence the complexity of a PC situation [14]. We believe the association between age and complexity may arise from the greater conformity and adaptation of older patients and their family environment to the situation of terminal illness.

The need for specialised PC and the intensity of the intervention required depend mainly on the palliative complexity presented by the patient. However, most previous studies have focused on the detection of needs, in order to identify patients who would benefit from end-of-life PC, but have not taken into consideration the degree of complexity that may be present. As regards the detection of needs, diverse criteria have been proposed [35–37] and measurement instruments have been devised, including the Scottish Prognostic Indicator Tool (SPICT) [38], the Gold Standards Framework Prognostic Indicator Guidance (PIG-GSF) [39] and the NECPAL (palliative needs) instrument [40]. With respect to patients and their families, complexity involves aspects such as age, background, comorbidity, the intensity of symptoms, functional, emotional and social status, prognosis, family members’ ability to care for the patient and the interaction among all these elements. Further complexity can arise according to the interventions proposed and implemented, in areas such as their intensity, duration and diagnostic or therapeutic difficulty, the resources needed and problems affecting decision making [18].

Much has been written regarding the need for PC and the benefits of earlier referral, but little research has been conducted regarding the use of screening tools to improve the identification of patients in need of more resource-intensive specialised PC, distinguishing them from those for whom a more generalist approach is sufficient [37]. The aspect of particular interest in the present study is that it analyses the results obtained for a sizeable population from the use of the IDC-Pal©, an instrument that has been developed to evaluate PC complexity comprehensively, rapidly and objectively. We believe the use of this instrument could improve the quality of PC, facilitating the use of a shared-care model applied according to the degree of complexity presented. Moreover, the use of IDC-Pal© throughout the follow-up process would enable managers to detect and react to the changing complexity of the case (taking into account that the severity of the case and the patient’s needs may vary during the course of the illness).

The present study has certain limitations that should be acknowledged. The study population was selected from a single healthcare environment, a circumstance that might restrict its external validity. Nevertheless, we believe the patients examined in this study are representative of the population of advanced-stage cancer patients in a specialised PC setting. The sociodemographic
data obtained, the prevalence of primary cancer and the presence of symptoms are all comparable with previously-reported data [41–43]. Another limitation to this study is its cross-sectional design, which does not allow causal relationships to be established, although it can detect factors related to complexity. In addition, the data collection were retrospective, which made them dependent on the quality of the information present in the medical records consulted. Furthermore, although the type and magnitude of complexity may change in the course of the disease, it was only evaluated in the first assessment.

On the other hand, our research also has significant strengths, especially the fact that the study population was considerably larger than those analysed in previous studies of complexity [21,23,24,41–43]. In consequence, a substantial and diverse body of clinical and functional data was collected, underpinning the statistical analysis performed. In our opinion, this type of study helps identify items and clinical conditions that may be predictive of complexity and, therefore, can help decision-making regarding the optimum time for referring the patient for specialised PC, as well as assisting intra-case management.

5. Conclusions

In conclusion, this study confirms the high level of complexity presented by many patients referred to a PC centre. Although the elements of complexity found to be most prevalent are those related to the patients’ clinical evolution, aspects of their socio-family environment also play a significant role. Greater knowledge of factors related to this complexity could help identify signals that would enable clinicians to improve the timing of referral for specialised PC. In our opinion, clinicians should take into account the complexity of the situation when PPS is less than 40%. Awareness of this consideration could be very useful for health professionals providing end-of-life care. Finally, the use of structured instruments to identify the level of complexity presented by a patient could help clinicians decide the most appropriate intensity of intervention required within a shared-care model.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/6/1960/s1, Table S1: Diagnostic Tool for Complexity Classification in Palliative Care (IDC-Pal©).

Author Contributions: Conceptualization, E.B.-R., M.I.C.-Z., R.G.-G.; methodology, E.B.-R., M.I.C.-Z., R.O.-R.; software, E.B.-R., M.I.C.-Z., R.O.-R.; validation, E.B.-R., M.I.C.-Z., R.G.-G.; formal analysis, E.B.-R., R.O.-R.; investigation, E.B.-R., M.I.C.-Z., R.G.-G.; resources, E.B.-R., M.I.C.-Z., R.G.-G., M.L.M.-R.; data curation, E.B.-R., M.I.C.-Z., R.O.-R.; writing—original draft preparation, E.B.-R., M.I.C.-Z.; writing—review & editing, E.B.-R., M.I.C.-Z., R.G.-G., R.O.-R., M.L.M.-R.; visualization, E.B.-R., M.I.C.-Z.; supervision, E.B.-R.; project administration, E.B.-R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Connor, S.; Sepulveda, C. The Global Atlas of Palliative Care at the End of Life, 1st ed.; Worldwide Hospice Palliative Care Alliance: London, UK, 2014; pp. 5–8.
2. Kavalieratos, D.; Corbelli, J.; Zhang, D.; Dionne-Odom, J.N.; Ernecco, N.C.; Hamner, J.; Hoydich, Z.P.; Ikejiani, D.Z.; Klein-Fedyshin, M.; Zimmermann, C.; et al. Association between palliative care and patient and caregiver outcomes: A systematic review and meta-analysis. JAMA 2016, 316, 2104–2114. [CrossRef] [PubMed]
3. Bakitas, M.; Lyons, K.D.; Hegel, M.T.; Balan, S.; Brokaw, F.C.; Seville, J.; Hull, J.G.; Li, Z.; Tosteson, T.D.; Byock, I.R.; et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: The project ENABLE II randomized controlled trial. JAMA 2009, 302, 741–749. [CrossRef] [PubMed]
4. Yennurajalingam, S.; Urbauer, D.L.; Casper, K.L.; Reyes-Gibby, C.C.; Chacko, R.; Poulter, V.; Bruera, E. Impact of a palliative care consultation team on cancer related symptoms in advanced cancer patients referred to an outpatient supportive care clinic. J. Pain Symptom Manag. 2011, 41, 49–56. [CrossRef]
5. Gade, G.; Venohr, I.; Conner, D.; MacGrady, K.; Beane, J.; Richardson, R.H.; Williams, M.P.; Liberson, M.; Blum, M.; Della, P.R. Impact of an inpatient palliative care team: A randomized control trial. J. Palliat. Med. 2008, 11, 180–190. [CrossRef]
6. Brumley, R.; Enguidanos, S.; Jamison, P.; Seitz, R.; Morgenstern, N.; Saito, S.; Mellwane, J.; Hillary, K.; Gonzalez, J. Increased satisfaction with care and lower costs: Results of a randomized trial of in-home palliative care. J. Am. Geriatr. Soc 2007, 55, 993–1000. [CrossRef]

7. Murtagh, F.E.M.; Bausewein, C.; Verne, J.; Groeneweld, E.I.; Kaloki, Y.E.; Higginson, I.J. How many people need palliative care? A study developing and comparing methods for population-based estimates. Palliat. Med. 2014, 28, 49–58. [CrossRef]

8. Etkind, S.N.; Bone, A.E.; Gomes, B.; Lovell, N.; Evans, C.J.; Higginson, I.J.; Murtagh, F.E.M. How many people will need palliative care in 2040? Past trends, future projections and implications for services. BMC Palliat. Care 2017, 15, 102. [CrossRef]

9. Morrison, R.S.; Meier, D.E. It’s all a matter of perspective. J. Palliat. Med. 2016, 19, 900–901. [CrossRef] [PubMed]

10. Molin, Y.; Gallay, C.; Gautier, J.; Lardy-Cleaud, A.; Mayet, R.; Grach, M.C.; Guesdon, G.; Capodano, G.; Dubroeucq, O.; Boulec, C.; et al. PALLIA-10, a screening tool to identify patients needing palliative care referral in comprehensive cancer centers: A prospective multicentric study (PREPA-10). Cancer Med. 2019, 8, 2950–2961. [CrossRef] [PubMed]

11. Bennett, M.; Adam, J.; Alison, D.; Hicks, F.; Stockton, M. Leeds eligibility criteria for specialist palliative care services. Palliat. Med. 2000, 14, 157–158. [CrossRef] [PubMed]

12. Quill, T.E.; Abernethy, A.P. Generalist plus specialist palliative care: Creating a more sustainable model. N. Engl. J. Med. 2013, 368, 1173–1175. [CrossRef] [PubMed]

13. Arias-Casais, N.; Garralda, E.; Rhee, J.; Lima, L.; Pons-Izquierdo, J.; Clark, D.; Hasselaar, J.; Ling, J.; Mosoiu, D.; Centeno-Cortes, C. EAPC Atlas of Palliative Care in Europe; EAPC Press: Vilvoorde, Belgium, 2019.

14. Hodiamont, F.; Jünger, S.; Leidl, R.; Maier, B.O.; Schildmann, E.; Bausewein, C. Understanding complexity-The palliative care situation as a complex adaptive system. BMC Health Serv. Res. 2019, 19, 157. [CrossRef] [PubMed]

15. Pask, S.; Pinto, C.; Bristowe, K.; Van Vliet, L.; Nicholson, C.; Evans, C.J.; George, R.; Bailey, K.; Davies, J.; Guo, P.; et al. A framework for complexity in palliative care: A qualitative study with patients, family carers and professionals. Palliat. Med. 2018, 32, 1078–1090. [CrossRef] [PubMed]

16. Cardu, A.; Gómez, M.; Prat, A. Predictive model of complexity in early palliative care: A cohort of advanced cancer patients (PALCOM study). Support Care Cancer 2018, 26, 241–249. [CrossRef] [PubMed]

17. Estrategia en Cuidados Paliativos del Sistema Nacional de Salud. Actualización 2010–2014. Ministerio de Sanidad, Política Social e Igualdad: Madrid, Spain, 2011. Available online: http://www.mscbs.gob.es/organizacion/sns/planCalidadSNS/docs/paliativos/cuidadospaliativos.pdf. (accessed on 26 November 2019).

18. Martin-Roselló, M.L.; Sanz-Amores, M.R.; Salvador-Comino, M.R. Instruments to evaluate complexity in end-of-life care. Curr. Opin. Support. Palliat. Care 2018, 12, 480–488. [CrossRef]

19. Esteban-Perez, M.; Graub, I.; Castells, G.; Bullich, Í.; Busquet, X.; Aranzana, A.; Besora, M.I.; Picaza, J.M.; Tuca, A.; Valverde, E. Complexity of end-of-life care: Levels of intervention in community health care. Med. Paliat. 2015, 22, 69–80. [CrossRef]

20. Hui, D.; Mori, M.; Meng, Y.C.; Watanabe, S.; Caraceni, A.; Strasser, F.; Saarto, T.; Cherny, N.; Glare, P.; Kaasa, S.; et al. Automatic referral to standardize palliative care access: An international Delphi survey. Support. Care Cancer 2018, 26, 175–180. [CrossRef]

21. Tuca, A.; Gómez, M.; Prat, A. Predictive model of complexity in early palliative care: A cohort of advanced cancer patients (PALCOM study). Support Care Cancer 2018, 26, 241–249. [CrossRef] [PubMed]

22. Martin-Roselló, M.L.; Fernández-López, A.; Sanz-Amores, R.; Gómez-García, R.; Vidal-España, F.; Cia-Ramos, R. IDC-Pal (Instrumento Diagnóstico de la Complejidad en Cuidados Paliativos) © Consejería de Igualdad, Salud y Políticas sociales. Fundación Cudeca. 2014. Available online: https://www.juntadeandalucia.es/export/drupaljda/salud_5af1956edd07e_idc_pal_2014.pdf. (accessed on 20 December 2019).

23. De Miguel, C.; Ruiz, S.; De la Uz, A.; Merino, E.; Gutierrez, A.; Sanz, L.; Molinero, E.; Sanz, E.; Navarro, A.; Riestra, A. Are the patients attended by home care support teams complex? Med. Paliat. 2018, 25, 7–16. [CrossRef]
24. Salvador, M.R.; Garrido, N.; Perea, I.; Martin, M.L.; Regife, V.; Fernández, A. The value of the Diagnostic Tool for complexity in Palliative Care for the assessment of palliative patients. *Med. Palliat.* 2017, 24, 196–203. [CrossRef]

25. Llobera, J.; Sansó, N.; Ruiz, A.; Llagostera, M.; Serratusell, E.; Serrano, C.; Martin, M.L.; Benito, E.; Castaño, E.J.; Leiva, A. Strongening primary health care teams with palliative care leaders: Protocol for a cluster randomized clinical trial. *BMC Palliat. Care* 2017, 24, 196–203. [CrossRef] [PubMed]

26. Mahoney, F.I.; Barthel, D.W. Functional evaluation: Barthel index. *Md State Med. J.* 1965, 14, 61–65.

27. Anderson, F.; Downing, G.M.; Hill, J.; Casorso, L.; Lerch, N. Palliative Performance Scale (PPS): A New Tool. *J. Palliat. Care* 1996, 12, 5–11. [CrossRef] [PubMed]

28. Hosmer, D.W.; Lemeshow, S.; Sturdivant, R.X. *Applied Logistic Regression*, 3rd ed.; John Wiley & Sons: Hoboken, NJ, USA, 2013.

29. Anderson, F.; Downing, M.; Hill, J.; Casorso, L.; Lerch, N. Palliative Performance Scale (PPS): A New Tool. *J. Palliat. Care* 1996, 12, 5–11. [CrossRef] [PubMed]

30. Lau, F.; Maida, V.; Downing, M.; Lesperance, M.; Karlson, N.; Kuziemsky, C. Use of the Palliative Performance Scale (PPS) for end-of-life prognostication in a palliative medicine consultation service. *J. Pain Symptom Manag.* 2009, 37, 965–972. [CrossRef] [PubMed]

31. Baik, D.; Russel, D.; Jordan, L.; Dooley, F.; Bowles, K.; Masterson, R.M. Using the Palliative Performance Scale to estimate survival for patients at the end of life: A systematic review of the literature. *J. Palliat. Med.* 2018, 21, 1651–1660. [CrossRef]

32. Sutradhar, R.; Seow, H.; Earle, C.; Dudgeon, D.; Atzema, C.; Husain, A.; Howell, D.; Liu, Y.; Sussman, J.; Barbera, L. Modeling the Longitudinal Transitions of Performance Status in Cancer Outpatients: Time to Discuss Palliative Care. *J. Pain Symptom Manag.* 2013, 45, 726–734. [CrossRef]

33. Seow, H.; Barbera, L.; Sutradhar, R.; Howell, D.; Dudgeon, D.; Atzema, C.; Liu, Y.; Husain, A.; Sussman, J.; Earle, C. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. *J. Clin. Oncol.* 2011, 29, 1151–1158. [CrossRef] [PubMed]

34. Olajide, O.; Hanson, L.; Usher, B.M.; Qaqish, B.F.; Schwartz, R.; Bernard, S. Validation of the Palliative Performance Scale in the Acute Tertiary Care Hospital Setting. *J. Pall Med.* 2007, 10, 111–117. [CrossRef]

35. Weissman, D.E.; Meier, D.E. Identifying patients in need of a palliative care assessment in the hospital setting: A consensus report from the center to advance palliative care. *J. Palliat. Med.* 2011, 14, 17–23. [CrossRef]

36. Hui, D.; Mori, M.; Watanabe, S.M.; Caraceni, A.; Strasser, F.; Saarto, T.; Glare, P.; Kaasa, S.; Bruera, E. Referral criteria for outpatient specialty palliative care: An international consensus. *Lancet Oncol.* 2016, 17, 552–559. [CrossRef]

37. Glare, P.; Plakovic, K.; Scholoms, A.; Egan, B.; Epstein, A.; Kelsen, D.; Saltz, L. Study using the NCCN guidelines for palliative care to screen patients for palliative care needs and referral to palliative care specialists. *J. Natl. Compr. Cancer Netw.* 2013, 11, 1087–1096. [CrossRef] [PubMed]

38. Highet, G.; Crawford, D.; Murray, S.A.; Boyd, K. Development and evaluation of the Supportive and Palliative Care Indicators Tool (SPICT): A mixed-methods study. *BMJ Support. Palliat. Care* 2014, 4, 285–290. [CrossRef] [PubMed]

39. O’Callaghan, A.; Laking, G.; Frey, R.; Robinson, J.; Gott, M. Can we predict which hospitalised patients are in their last year of life? A prospective crosssectional study of the Gold Standards Framework Prognostic Indicator Guidance as a screening tool in the acute hospital setting. *Palliat. Med.* 2014, 28, 1046–1052. [CrossRef] [PubMed]

40. Gómez, X.; Martínez, M.; Blay, C.; Amblàs, J.; Vila, L.; Costa, X.; Villanueva, A.; Espaulella, J.; Espinosa, J.; Figuerola, M.; et al. Identifying patients with chronic conditions in need of palliative care in the general population: Development of the NECPAL tool and preliminary prevalence rates in Catalonia. *BMJ Support. Palliat. Care* 2013, 3, 300–308. [CrossRef] [PubMed]

41. Tuca, A.; Gómez, X.; Espinosa, J.; Martínez, M.; Cordorniu, N.; Porta, J. Structure, organisation and clinical outcomes in cancer patients of hospital support teams in Spain. *BMJ Support. Palliat. Care* 2012, 2, 356–362. [CrossRef] [PubMed]
42. Ryan, T.; Ingleton, C.; Gardiner, C.; Parker, C.; Gott, M.; Noble, B. Symptom burden, palliative care need and predictors of physical and psychological discomfort in two UK hospitals. *BMC Palliat. Care* **2013**, *12*, 11. [CrossRef]

43. Teunissen, S.C.; Wesker, W.; Kruitwagen, C.; De Haes, H.C.; Voest, E.E.; De Graeff, A. Symptom prevalence in patients with incurable cancer: A systematic review. *J. Pain Symptom Manag.* **2007**, *34*, 94–104. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).